title: [Changes of content of regulatory lymphocytes and concentration of soluble interleukine-2 receptor in blood of patients with ischemic heart disease after coronary artery angioplasty with implantation of stents with rapamycin covering].
abstract: We studied dynamics of content of subpopulation of lymphocytes including regulatory and effector T-lymphocytes as well as concentration of soluble form of interleukine-2 receptor (sCD25) in peripheral blood of patients after coronary stenting (CS) with implantation of stents with rapamycin covering (SRC). We included into the study 62 patients with stable effort II-III functional class angina. Coronary angiography (CA) was carried out in all, CS with implantation of 1 - 2 SRC - in 42 patients. Blood samples were taken before CA/CS, in 24, 48 hours, 7 days, 1 and 3 months after intervention. Content of T-, helper and cytotoxic T-cells, -, NK-, NKT-cells, activated effector T-lymphocytes (CD4+CD251owCD127high) and regulatory T-lymphocytes (CD4+CD25highCD1271ow) were measured by direct immunofluorescence and flow cytometry. CD4+ lymphocytes were isolated from mononuclear cell fraction of donor blood by magnetic separation. Content of regulatory T-lymphocytes in culture were determined by expression of a specific marker FOXP3+. Concentration of sCD25 was measured by chemiluminescent method. It was shown that content of main subpopulations of lymphocytes in blood changed after CS or CF. Blood content of regulatory T-lymphocytes and sCD25 significantly increased after 7 days and 1 month after CS but not after CA. Plasma sCD25 concentration correlated with content of regulatory T-lymphocytes in 1 month after SRC implantation. During cultivation of CD4+ lymphocytes in the presence of rapamycin we noted antiproliferative effect relative to FOXP3-cells and accumulation of regulatory +-lymphocytes. Thus implantation of SRC in coronary arteries leads to increase of number of circulating regulatory T-lymphocytes and blood concentration of sCD25. Changes of these parameters after CS can reflect peculiarities of local and systemic reaction arising in response to introduction of stent with drug covering and be significant for assessment of prognosis of the disease.
authors.forename: A V
authors.initials: AV
authors.lastname: Potekhina
authors.forename: V O
authors.initials: VO
authors.lastname: Sokolov
authors.forename: E A
authors.initials: EA
authors.lastname: Pylaeva
authors.forename: S I
authors.initials: SI
authors.lastname: Provatorov
authors.forename: V P
authors.initials: VP
authors.lastname: Masenko
authors.forename: E G
authors.initials: EG
authors.lastname: Bosykh
authors.forename: E A
authors.initials: EA
authors.lastname: Noeva
authors.forename: T L
authors.initials: TL
authors.lastname: Krasnikova
authors.forename: T I
authors.initials: TI
authors.lastname: Aref'eva
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D017023:Coronary Angiography; D016503:Drug Delivery Systems; D054855:Drug-Eluting Stents; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012720:Severity of Illness Index; D020123:Sirolimus / Q000008:administration & dosage* / Q000493:pharmacokinetics; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism*
chemical_list: D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D020123:Sirolimus